Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer

NCT07132008 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

94

Enrollment

OTHER

Sponsor class

Conditions

Colonic Neoplasms
Neoadjuvant Therapy
Immune Checkpoint Inhibitors

Interventions

DRUG: Tislelizumab
DRUG: Oxaliplatin
DRUG: Capecitabine

Sponsor

First Affiliated Hospital of Guangxi Medical University

Collaborators

[object Object]
[object Object]